Effervescent calcium carbasalate is a calcium-salt of acetylsalicylic acid causing less local gastric damage than acetylsalicylic acid at high doses in healthy controls.
|The peptic ulcer risk was 3 per 1000 person-years with acetylsalicylic acid|
|Clinical Gastroenterology & Hepatology|
Dr Martijn van Oijen and colleagues from the Netherlands investigated the incidence of peptic ulcers in a population-based cohort using bioequivalent low-dose acetylsalicylic acid or effervescent calcium carbasalate.
The research team identified incident acetylsalicylic acid or effervescent calcium carbasalate users from the Integrated Primary Care Information database.
The study cohort comprised 19,819 subjects, of which 11,891 received acetylsalicylic acid, and 7,928 received effervescent calcium carbasalate.
Incidence rates for documented peptic ulcer disease confirmed by endoscopy were calculated.
Time-dependent adjusted Cox regression analysis was used to compare the risk of peptic ulcers for patients using acetylsalicylic acid or effervescent calcium carbasalate.
The team found 115 ulcers during an average 2 years of follow-up evaluation.
The risk for developing a peptic ulcer during drug use was 3 per 1000 person-years for acetylsalicylic acid, and 4 for effervescent calcium carbasalate.
The team found that the risk of peptic ulcers was not statistically significantly higher in patients using effervescent calcium carbasalate than in acetylsalicylic acid users.
Dr van Oijens' team concluded, "The incidence rate of peptic ulcer disease is similar in patients using low-dose effervescent calcium carbasalate compared with regular low-dose acetylsalicylic acid."
"This implicates that peptic ulcers seem to be related to systemic rather than to local effects of low-dose acetylsalicylic acid."